Abstract
Objectives Mobile health clinics (MHCs) provide flexible, community-based care to underserved populations facing geographic and socioeconomic barriers. Maximizing coverage enables MHCs to reach more individuals, improve preventive and continuous care, and reduce health disparities. However, few strategies exist to guide placement and routing decisions. We present a framework to increase MHC utilization by optimizing service coverage.
Study Design This is a retrospective study.
Methods We analyzed MHC deployments for Hepatitis C Virus (HCV) screening and treatment from a local health system in South Carolina. We used a location-allocation model to identify potential MHC placement sites that maximized the number of uninsured residents within a 5-minute drive or 10-minute walk. Demand was represented by block centroids weighted by the size of the uninsured population. We compared service area population, defined as the size of the target population within driving or walking distance, for model-proposed sites with coverage from previous MHC deployments. We fit negative binomial mixed effects models to evaluate the association between service area population and MHC utilization.
Results Optimized placements can nearly double population coverage, expanding access to uninsured residents within practical travel distances by 90% for driving and 135% for walking—without requiring additional vehicles or resources. This approach also substantially reduces redundant service areas while shortening average travel times. Results show that small geographic shifts can yield significant improvements. In rural regions, greater geographic coverage is significantly associated with higher MHC utilization for HCV screening (drive p=.0037; walk p=.0095). We applied this framework with local health partners to guide real-world MHC deployment in South Carolina.
Conclusions This framework connects spatial analytics to service delivery, offering a replicable, operationally ready tool adaptable to various travel modes, site types, and disease contexts. It supports strategic placement in high-need locations by reducing travel time and service redundancy and ultimately improving health outcomes in medically underserved populations.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the National Library of Medicine of the National Institutes of Health (R01LM014193), the National Institute on Drug Abuse of the National Institutes of Health (R33DA059892), and the Center for Forecasting and Outbreak Analytics of the Centers for Disease Control and Prevention (NU38FT000011). The HCV screening and treatment program was supported by Gilead Sciences, Inc., (IN-US-987-5892) with additional funding specifically for uninsured patients from South Carolina Center for Rural and Primary Healthcare (2015593). The funders had no role in the design, conduct, reporting of the study, or decision to submit for publication. During the preparation of this work the authors used ChatGPT-5 (OpenAI) to improve readability and clarity in parts of the manuscript. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Institutional Review Board of Clemson University (Protocol #IRB2022-0150) and by the Prisma Health institutional review board (IRB Pro 00106348).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Email: shtanim{at}gmail.com Email: whitedl{at}clemson.edu, Email: bwitric{at}clemson.edu, Email: liorr{at}clemson.edu
Data sharing
Community-level data is publicly available and can be accessed through the United States Census Bureau American Community Survey. Due to patient confidentiality, data from Clemson Rural Health’s HCV screening program cannot be shared.
